Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ketoconazole + clobetasol propionate + neomycin sulfate
- Development stage
- Unknown
- Lead developer
- Geneith Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Ketineal is a topical triple-action combination cream developed and marketed by Geneith Pharmaceuticals. It contains the super-high potency corticosteroid clobetasol propionate, the azole antifungal ketoconazole, and the aminoglycoside antibiotic neomycin sulfate. This combination is indicated for the short-term treatment of complex, inflammatory skin conditions complicated by secondary bacterial and/or fungal infections, such as severe eczema, psoriasis, seborrheic dermatitis, and various tinea infections (including athlete's foot, jock itch, and ringworm). Clobetasol propionate acts as an agonist of the glucocorticoid receptor to reduce inflammation, redness, and itching. Ketoconazole inhibits fungal lanosterol 14-alpha demethylase, disrupting ergosterol synthesis and fungal cell membrane integrity. Neomycin sulfate binds to the bacterial 30S ribosomal subunit, inhibiting protein synthesis and providing broad-spectrum antibacterial activity.
- Brand names
- Ketineal
- Other names
- Ketineal Creamketoconazole + clobetasol + neomycinketoconazole + clobetasol propionate + neomycinketoconazole + clobetasol propionate + neomycin sulfate
02
Targets
CYP51A1 (Sterol 14α-demethylase)GR (Glucocorticoid receptor)Mitoribosome (Mitochondrial ribosome)Bacterial Ribosome
Beyond the preview
Go deeper on ketoconazole + clobetasol propionate + neomycin sulfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ketoconazole + clobetasol propionate + neomycin sulfate.